Compare NTCT & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NTCT | CDNA |
|---|---|---|
| Founded | 1984 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 2.6B |
| IPO Year | 1999 | 2007 |
| Metric | NTCT | CDNA |
|---|---|---|
| Price | $38.09 | $54.01 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 6 |
| Target Price | ★ $31.00 | $28.00 |
| AVG Volume (30 Days) | 557.4K | ★ 1.0M |
| Earning Date | 05-07-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 125.39 | N/A |
| EPS | 0.29 | ★ 2.13 |
| Revenue | ★ $891,820,000.00 | $48,324,000.00 |
| Revenue This Year | $6.02 | $16.01 |
| Revenue Next Year | $2.55 | $11.31 |
| P/E Ratio | $135.41 | ★ $25.48 |
| Revenue Growth | N/A | ★ 18.93 |
| 52 Week Low | $25.20 | $13.95 |
| 52 Week High | $45.28 | $55.16 |
| Indicator | NTCT | CDNA |
|---|---|---|
| Relative Strength Index (RSI) | 47.69 | 71.60 |
| Support Level | $36.53 | $45.74 |
| Resistance Level | $39.84 | N/A |
| Average True Range (ATR) | 0.92 | 2.18 |
| MACD | 0.20 | 0.02 |
| Stochastic Oscillator | 53.21 | 89.49 |
NetScout Systems Inc is engaged in providing enterprise network observability, carrier service assurance, cybersecurity, and Distributed Denial-of-Service (DDoS), protection solutions. It bases its solutions on proprietary adaptive service intelligence technology, which helps customers monitor and identify performance issues and provides insight into network-based security threats. These solutions also deliver real-time and historical information, which provides insight to restore service and understand the quality of user experience. The company derives revenue from the sale of network management tools and security solutions. Its geographical regions include USA, which derives maximum revenue, Europe, Asia, and Rest of the World.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically it generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.